Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies

Cancer immunotherapy by immune checkpoint blockade has proven its great potential by saving the lives of a proportion of late stage patients with immunogenic tumor types. However, even in these sensitive tumor types, the majority of patients do not sufficiently respond to the therapy. Furthermore, o...

Full description

Saved in:
Bibliographic Details
Published in:eLife 2020-02, Vol.9
Main Authors: Pombo Antunes, Ana Rita, Scheyltjens, Isabelle, Duerinck, Johnny, Neyns, Bart, Movahedi, Kiavash, Van Ginderachter, Jo A
Format: Article
Language:English
Subjects:
Brain - cytology
Brain - immunology
Brain - metabolism
Brain cancer
Brain Neoplasms - immunology
Brain Neoplasms - therapy
Cancer
Cancer Biology
Cancer cells
Cancer immunotherapy
Cancer therapies
Cancer treatment
Dendritic cells
Dendritic Cells - cytology
Dendritic Cells - immunology
Destruction
Glioblastoma
Glioblastoma - immunology
Glioblastoma - therapy
Glioblastomas
Gliomas
Health aspects
Humans
Immune checkpoint
Immune response
Immunogenicity
Immunoglobulins
Immunoregulation
Immunostimulation
Immunosuppressive agents
Immunotherapy
Lymphocytes
Lymphocytes T
Macrophages
Macrophages - cytology
Macrophages - immunology
Melanoma
microenvironment
Nivolumab
Ontogeny
Pembrolizumab
Radiation therapy
regulatory T cell
Review
Spatial distribution
Stem cells
T cells
T-Lymphocytes, Regulatory - cytology
T-Lymphocytes, Regulatory - immunology
Tumor Microenvironment - immunology
tumor-associated dendritic cell
tumor-associated macrophage
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c684t-aad6ae9f635433569d5f1833ea20750ca89e4199697375545454fa8ba2ccd8243
cites cdi_FETCH-LOGICAL-c684t-aad6ae9f635433569d5f1833ea20750ca89e4199697375545454fa8ba2ccd8243
container_end_page
container_issue
container_start_page
container_title eLife
container_volume 9
creator Pombo Antunes, Ana Rita
Scheyltjens, Isabelle
Duerinck, Johnny
Neyns, Bart
Movahedi, Kiavash
Van Ginderachter, Jo A
description Cancer immunotherapy by immune checkpoint blockade has proven its great potential by saving the lives of a proportion of late stage patients with immunogenic tumor types. However, even in these sensitive tumor types, the majority of patients do not sufficiently respond to the therapy. Furthermore, other tumor types, including glioblastoma, remain largely refractory. The glioblastoma immune microenvironment is recognized as highly immunosuppressive, posing a major hurdle for inducing immune-mediated destruction of cancer cells. Scattered information is available about the presence and activity of immunosuppressive or immunostimulatory cell types in glioblastoma tumors, including tumor-associated macrophages, tumor-infiltrating dendritic cells and regulatory T cells. These cell types are heterogeneous at the level of ontogeny, spatial distribution and functionality within the tumor immune compartment, providing insight in the complex cellular and molecular interplay that determines the immune refractory state in glioblastoma. This knowledge may also yield next generation molecular targets for therapeutic intervention.
doi_str_mv 10.7554/elife.52176
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_bdbc95f3f2d646099ade0c71834ee533</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A613171821</galeid><doaj_id>oai_doaj_org_article_bdbc95f3f2d646099ade0c71834ee533</doaj_id><sourcerecordid>A613171821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c684t-aad6ae9f635433569d5f1833ea20750ca89e4199697375545454fa8ba2ccd8243</originalsourceid><addsrcrecordid>eNptkl1rFDEUhgdRbKm98l4GvFFk13xMZjI3Qil-LCwIasG7cCY5mWaZSdZkptV_b3a31q6YXCTkPOc9yZtTFM8pWTZCVG9xcBaXgtGmflScMiLIgsjq--MH-5PiPKUNyaOppKTt0-KEM0IrSprT4vbKG4xpAm-c78vpGst-cKEbIE1hhNKN4-yxHJ2OAf2Ni8GP6KcSUtlBcqm0Ie6zDN7gELb7YLClx9tDbsjBCFucJ6fLNEWYsHeYnhVPLAwJz-_Ws-Lqw_tvl58W688fV5cX64WuZTUtAEwN2Nqai4pzUbdGWCo5R2CkEUSDbLGibVu3Dd_5sZsWZAdMayNZxc-K1UHXBNiobXQjxF8qgFP7gxB7BTFfbUDVmU63wnLLTF3VpG3BINFNLlchCs6z1ruD1nbuRjQ6PzXCcCR6HPHuWvXhRjXZe0ZFFnh1JxDDjxnTpEaXNA4DeAxzUowL0hLJxa7Wy3_QTZijz1ZlqpaCSsLkX6qH_ADnbch19U5UXdSU03x5RjO1_A-Vp8H8r8Gjdfn8KOH1UUJmJvw59TCnpFZfvxyzbw5sbpCUItp7PyhRuy9RuM4tqvYtmukXDy28Z_80JP8NehDiLg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2368518028</pqid></control><display><type>article</type><title>Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><creator>Pombo Antunes, Ana Rita ; Scheyltjens, Isabelle ; Duerinck, Johnny ; Neyns, Bart ; Movahedi, Kiavash ; Van Ginderachter, Jo A</creator><creatorcontrib>Pombo Antunes, Ana Rita ; Scheyltjens, Isabelle ; Duerinck, Johnny ; Neyns, Bart ; Movahedi, Kiavash ; Van Ginderachter, Jo A</creatorcontrib><description>Cancer immunotherapy by immune checkpoint blockade has proven its great potential by saving the lives of a proportion of late stage patients with immunogenic tumor types. However, even in these sensitive tumor types, the majority of patients do not sufficiently respond to the therapy. Furthermore, other tumor types, including glioblastoma, remain largely refractory. The glioblastoma immune microenvironment is recognized as highly immunosuppressive, posing a major hurdle for inducing immune-mediated destruction of cancer cells. Scattered information is available about the presence and activity of immunosuppressive or immunostimulatory cell types in glioblastoma tumors, including tumor-associated macrophages, tumor-infiltrating dendritic cells and regulatory T cells. These cell types are heterogeneous at the level of ontogeny, spatial distribution and functionality within the tumor immune compartment, providing insight in the complex cellular and molecular interplay that determines the immune refractory state in glioblastoma. This knowledge may also yield next generation molecular targets for therapeutic intervention.</description><identifier>ISSN: 2050-084X</identifier><identifier>EISSN: 2050-084X</identifier><identifier>DOI: 10.7554/elife.52176</identifier><identifier>PMID: 32014107</identifier><language>eng</language><publisher>England: eLife Science Publications, Ltd</publisher><subject>Brain - cytology ; Brain - immunology ; Brain - metabolism ; Brain cancer ; Brain Neoplasms - immunology ; Brain Neoplasms - therapy ; Cancer ; Cancer Biology ; Cancer cells ; Cancer immunotherapy ; Cancer therapies ; Cancer treatment ; Dendritic cells ; Dendritic Cells - cytology ; Dendritic Cells - immunology ; Destruction ; Glioblastoma ; Glioblastoma - immunology ; Glioblastoma - therapy ; Glioblastomas ; Gliomas ; Health aspects ; Humans ; Immune checkpoint ; Immune response ; Immunogenicity ; Immunoglobulins ; Immunoregulation ; Immunostimulation ; Immunosuppressive agents ; Immunotherapy ; Lymphocytes ; Lymphocytes T ; Macrophages ; Macrophages - cytology ; Macrophages - immunology ; Melanoma ; microenvironment ; Nivolumab ; Ontogeny ; Pembrolizumab ; Radiation therapy ; regulatory T cell ; Review ; Spatial distribution ; Stem cells ; T cells ; T-Lymphocytes, Regulatory - cytology ; T-Lymphocytes, Regulatory - immunology ; Tumor Microenvironment - immunology ; tumor-associated dendritic cell ; tumor-associated macrophage ; Tumors</subject><ispartof>eLife, 2020-02, Vol.9</ispartof><rights>2020, Pombo Antunes et al.</rights><rights>COPYRIGHT 2020 eLife Science Publications, Ltd.</rights><rights>2020, Pombo Antunes et al. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020, Pombo Antunes et al 2020 Pombo Antunes et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c684t-aad6ae9f635433569d5f1833ea20750ca89e4199697375545454fa8ba2ccd8243</citedby><cites>FETCH-LOGICAL-c684t-aad6ae9f635433569d5f1833ea20750ca89e4199697375545454fa8ba2ccd8243</cites><orcidid>0000-0002-4442-7474</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2368518028/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2368518028?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32014107$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pombo Antunes, Ana Rita</creatorcontrib><creatorcontrib>Scheyltjens, Isabelle</creatorcontrib><creatorcontrib>Duerinck, Johnny</creatorcontrib><creatorcontrib>Neyns, Bart</creatorcontrib><creatorcontrib>Movahedi, Kiavash</creatorcontrib><creatorcontrib>Van Ginderachter, Jo A</creatorcontrib><title>Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies</title><title>eLife</title><addtitle>Elife</addtitle><description>Cancer immunotherapy by immune checkpoint blockade has proven its great potential by saving the lives of a proportion of late stage patients with immunogenic tumor types. However, even in these sensitive tumor types, the majority of patients do not sufficiently respond to the therapy. Furthermore, other tumor types, including glioblastoma, remain largely refractory. The glioblastoma immune microenvironment is recognized as highly immunosuppressive, posing a major hurdle for inducing immune-mediated destruction of cancer cells. Scattered information is available about the presence and activity of immunosuppressive or immunostimulatory cell types in glioblastoma tumors, including tumor-associated macrophages, tumor-infiltrating dendritic cells and regulatory T cells. These cell types are heterogeneous at the level of ontogeny, spatial distribution and functionality within the tumor immune compartment, providing insight in the complex cellular and molecular interplay that determines the immune refractory state in glioblastoma. This knowledge may also yield next generation molecular targets for therapeutic intervention.</description><subject>Brain - cytology</subject><subject>Brain - immunology</subject><subject>Brain - metabolism</subject><subject>Brain cancer</subject><subject>Brain Neoplasms - immunology</subject><subject>Brain Neoplasms - therapy</subject><subject>Cancer</subject><subject>Cancer Biology</subject><subject>Cancer cells</subject><subject>Cancer immunotherapy</subject><subject>Cancer therapies</subject><subject>Cancer treatment</subject><subject>Dendritic cells</subject><subject>Dendritic Cells - cytology</subject><subject>Dendritic Cells - immunology</subject><subject>Destruction</subject><subject>Glioblastoma</subject><subject>Glioblastoma - immunology</subject><subject>Glioblastoma - therapy</subject><subject>Glioblastomas</subject><subject>Gliomas</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immune checkpoint</subject><subject>Immune response</subject><subject>Immunogenicity</subject><subject>Immunoglobulins</subject><subject>Immunoregulation</subject><subject>Immunostimulation</subject><subject>Immunosuppressive agents</subject><subject>Immunotherapy</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Macrophages</subject><subject>Macrophages - cytology</subject><subject>Macrophages - immunology</subject><subject>Melanoma</subject><subject>microenvironment</subject><subject>Nivolumab</subject><subject>Ontogeny</subject><subject>Pembrolizumab</subject><subject>Radiation therapy</subject><subject>regulatory T cell</subject><subject>Review</subject><subject>Spatial distribution</subject><subject>Stem cells</subject><subject>T cells</subject><subject>T-Lymphocytes, Regulatory - cytology</subject><subject>T-Lymphocytes, Regulatory - immunology</subject><subject>Tumor Microenvironment - immunology</subject><subject>tumor-associated dendritic cell</subject><subject>tumor-associated macrophage</subject><subject>Tumors</subject><issn>2050-084X</issn><issn>2050-084X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkl1rFDEUhgdRbKm98l4GvFFk13xMZjI3Qil-LCwIasG7cCY5mWaZSdZkptV_b3a31q6YXCTkPOc9yZtTFM8pWTZCVG9xcBaXgtGmflScMiLIgsjq--MH-5PiPKUNyaOppKTt0-KEM0IrSprT4vbKG4xpAm-c78vpGst-cKEbIE1hhNKN4-yxHJ2OAf2Ni8GP6KcSUtlBcqm0Ie6zDN7gELb7YLClx9tDbsjBCFucJ6fLNEWYsHeYnhVPLAwJz-_Ws-Lqw_tvl58W688fV5cX64WuZTUtAEwN2Nqai4pzUbdGWCo5R2CkEUSDbLGibVu3Dd_5sZsWZAdMayNZxc-K1UHXBNiobXQjxF8qgFP7gxB7BTFfbUDVmU63wnLLTF3VpG3BINFNLlchCs6z1ruD1nbuRjQ6PzXCcCR6HPHuWvXhRjXZe0ZFFnh1JxDDjxnTpEaXNA4DeAxzUowL0hLJxa7Wy3_QTZijz1ZlqpaCSsLkX6qH_ADnbch19U5UXdSU03x5RjO1_A-Vp8H8r8Gjdfn8KOH1UUJmJvw59TCnpFZfvxyzbw5sbpCUItp7PyhRuy9RuM4tqvYtmukXDy28Z_80JP8NehDiLg</recordid><startdate>20200204</startdate><enddate>20200204</enddate><creator>Pombo Antunes, Ana Rita</creator><creator>Scheyltjens, Isabelle</creator><creator>Duerinck, Johnny</creator><creator>Neyns, Bart</creator><creator>Movahedi, Kiavash</creator><creator>Van Ginderachter, Jo A</creator><general>eLife Science Publications, Ltd</general><general>eLife Sciences Publications Ltd</general><general>eLife Sciences Publications, Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-4442-7474</orcidid></search><sort><creationdate>20200204</creationdate><title>Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies</title><author>Pombo Antunes, Ana Rita ; Scheyltjens, Isabelle ; Duerinck, Johnny ; Neyns, Bart ; Movahedi, Kiavash ; Van Ginderachter, Jo A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c684t-aad6ae9f635433569d5f1833ea20750ca89e4199697375545454fa8ba2ccd8243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Brain - cytology</topic><topic>Brain - immunology</topic><topic>Brain - metabolism</topic><topic>Brain cancer</topic><topic>Brain Neoplasms - immunology</topic><topic>Brain Neoplasms - therapy</topic><topic>Cancer</topic><topic>Cancer Biology</topic><topic>Cancer cells</topic><topic>Cancer immunotherapy</topic><topic>Cancer therapies</topic><topic>Cancer treatment</topic><topic>Dendritic cells</topic><topic>Dendritic Cells - cytology</topic><topic>Dendritic Cells - immunology</topic><topic>Destruction</topic><topic>Glioblastoma</topic><topic>Glioblastoma - immunology</topic><topic>Glioblastoma - therapy</topic><topic>Glioblastomas</topic><topic>Gliomas</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immune checkpoint</topic><topic>Immune response</topic><topic>Immunogenicity</topic><topic>Immunoglobulins</topic><topic>Immunoregulation</topic><topic>Immunostimulation</topic><topic>Immunosuppressive agents</topic><topic>Immunotherapy</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Macrophages</topic><topic>Macrophages - cytology</topic><topic>Macrophages - immunology</topic><topic>Melanoma</topic><topic>microenvironment</topic><topic>Nivolumab</topic><topic>Ontogeny</topic><topic>Pembrolizumab</topic><topic>Radiation therapy</topic><topic>regulatory T cell</topic><topic>Review</topic><topic>Spatial distribution</topic><topic>Stem cells</topic><topic>T cells</topic><topic>T-Lymphocytes, Regulatory - cytology</topic><topic>T-Lymphocytes, Regulatory - immunology</topic><topic>Tumor Microenvironment - immunology</topic><topic>tumor-associated dendritic cell</topic><topic>tumor-associated macrophage</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pombo Antunes, Ana Rita</creatorcontrib><creatorcontrib>Scheyltjens, Isabelle</creatorcontrib><creatorcontrib>Duerinck, Johnny</creatorcontrib><creatorcontrib>Neyns, Bart</creatorcontrib><creatorcontrib>Movahedi, Kiavash</creatorcontrib><creatorcontrib>Van Ginderachter, Jo A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Science (Gale in Context)</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Science Journals</collection><collection>ProQuest Biological Science Journals</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>eLife</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pombo Antunes, Ana Rita</au><au>Scheyltjens, Isabelle</au><au>Duerinck, Johnny</au><au>Neyns, Bart</au><au>Movahedi, Kiavash</au><au>Van Ginderachter, Jo A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies</atitle><jtitle>eLife</jtitle><addtitle>Elife</addtitle><date>2020-02-04</date><risdate>2020</risdate><volume>9</volume><issn>2050-084X</issn><eissn>2050-084X</eissn><abstract>Cancer immunotherapy by immune checkpoint blockade has proven its great potential by saving the lives of a proportion of late stage patients with immunogenic tumor types. However, even in these sensitive tumor types, the majority of patients do not sufficiently respond to the therapy. Furthermore, other tumor types, including glioblastoma, remain largely refractory. The glioblastoma immune microenvironment is recognized as highly immunosuppressive, posing a major hurdle for inducing immune-mediated destruction of cancer cells. Scattered information is available about the presence and activity of immunosuppressive or immunostimulatory cell types in glioblastoma tumors, including tumor-associated macrophages, tumor-infiltrating dendritic cells and regulatory T cells. These cell types are heterogeneous at the level of ontogeny, spatial distribution and functionality within the tumor immune compartment, providing insight in the complex cellular and molecular interplay that determines the immune refractory state in glioblastoma. This knowledge may also yield next generation molecular targets for therapeutic intervention.</abstract><cop>England</cop><pub>eLife Science Publications, Ltd</pub><pmid>32014107</pmid><doi>10.7554/elife.52176</doi><orcidid>https://orcid.org/0000-0002-4442-7474</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2050-084X
ispartof eLife, 2020-02, Vol.9
issn 2050-084X
2050-084X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_bdbc95f3f2d646099ade0c71834ee533
source Open Access: PubMed Central; Publicly Available Content Database (Proquest) (PQ_SDU_P3)
subjects Brain - cytology
Brain - immunology
Brain - metabolism
Brain cancer
Brain Neoplasms - immunology
Brain Neoplasms - therapy
Cancer
Cancer Biology
Cancer cells
Cancer immunotherapy
Cancer therapies
Cancer treatment
Dendritic cells
Dendritic Cells - cytology
Dendritic Cells - immunology
Destruction
Glioblastoma
Glioblastoma - immunology
Glioblastoma - therapy
Glioblastomas
Gliomas
Health aspects
Humans
Immune checkpoint
Immune response
Immunogenicity
Immunoglobulins
Immunoregulation
Immunostimulation
Immunosuppressive agents
Immunotherapy
Lymphocytes
Lymphocytes T
Macrophages
Macrophages - cytology
Macrophages - immunology
Melanoma
microenvironment
Nivolumab
Ontogeny
Pembrolizumab
Radiation therapy
regulatory T cell
Review
Spatial distribution
Stem cells
T cells
T-Lymphocytes, Regulatory - cytology
T-Lymphocytes, Regulatory - immunology
Tumor Microenvironment - immunology
tumor-associated dendritic cell
tumor-associated macrophage
Tumors
title Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T16%3A15%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Understanding%20the%20glioblastoma%20immune%20microenvironment%20as%20basis%20for%20the%20development%20of%20new%20immunotherapeutic%20strategies&rft.jtitle=eLife&rft.au=Pombo%20Antunes,%20Ana%20Rita&rft.date=2020-02-04&rft.volume=9&rft.issn=2050-084X&rft.eissn=2050-084X&rft_id=info:doi/10.7554/elife.52176&rft_dat=%3Cgale_doaj_%3EA613171821%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c684t-aad6ae9f635433569d5f1833ea20750ca89e4199697375545454fa8ba2ccd8243%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2368518028&rft_id=info:pmid/32014107&rft_galeid=A613171821&rfr_iscdi=true